HSDT vs. CHFS, NUWE, TIVC, NDRA, NBSE, BDRX, NMRD, GRI, BJDX, and CANOQ
Should you be buying Helius Medical Technologies stock or one of its competitors? The main competitors of Helius Medical Technologies include Nuwellis (CHFS), Nuwellis (NUWE), Tivic Health Systems (TIVC), ENDRA Life Sciences (NDRA), NeuBase Therapeutics (NBSE), Biodexa Pharmaceuticals (BDRX), Nemaura Medical (NMRD), GRI Bio (GRI), Bluejay Diagnostics (BJDX), and Cano Health (CANOQ). These companies are all part of the "medical" sector.
Nuwellis (NASDAQ:CHFS) and Helius Medical Technologies (NASDAQ:HSDT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, institutional ownership, dividends, profitability, media sentiment, community ranking, analyst recommendations, earnings and valuation.
65.1% of Nuwellis shares are held by institutional investors. Comparatively, 18.6% of Helius Medical Technologies shares are held by institutional investors. 0.6% of Nuwellis shares are held by insiders. Comparatively, 7.3% of Helius Medical Technologies shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
In the previous week, Helius Medical Technologies had 6 more articles in the media than Nuwellis. MarketBeat recorded 6 mentions for Helius Medical Technologies and 0 mentions for Nuwellis. Nuwellis' average media sentiment score of 0.12 beat Helius Medical Technologies' score of 0.00 indicating that Helius Medical Technologies is being referred to more favorably in the news media.
Helius Medical Technologies has lower revenue, but higher earnings than Nuwellis. Helius Medical Technologies is trading at a lower price-to-earnings ratio than Nuwellis, indicating that it is currently the more affordable of the two stocks.
Helius Medical Technologies has a consensus price target of $24.00, suggesting a potential upside of 1,521.62%. Given Nuwellis' higher probable upside, analysts clearly believe Helius Medical Technologies is more favorable than Nuwellis.
Nuwellis has a net margin of -254.26% compared to Nuwellis' net margin of -1,328.14%. Helius Medical Technologies' return on equity of -173.61% beat Nuwellis' return on equity.
Nuwellis has a beta of 1.55, indicating that its share price is 55% more volatile than the S&P 500. Comparatively, Helius Medical Technologies has a beta of 1.6, indicating that its share price is 60% more volatile than the S&P 500.
Nuwellis received 304 more outperform votes than Helius Medical Technologies when rated by MarketBeat users. Likewise, 69.53% of users gave Nuwellis an outperform vote while only 57.14% of users gave Helius Medical Technologies an outperform vote.
Summary
Helius Medical Technologies beats Nuwellis on 10 of the 17 factors compared between the two stocks.
Get Helius Medical Technologies News Delivered to You Automatically
Sign up to receive the latest news and ratings for HSDT and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HSDT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Helius Medical Technologies Competitors List
Related Companies and Tools
